Quoin Pharmaceuticals Ltd ((QNRX)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Quoin Pharmaceuticals Ltd is conducting a clinical study titled ‘A Single Center, Open Label, Expanded Access Study of QRX003 Lotion in Subjects With Netherton Syndrome.’ The study aims to evaluate the effectiveness and safety of QRX003, a topical lotion, in treating Netherton syndrome, a genetic skin disorder. The primary objectives are to assess the improvement in clinical symptoms and identify any medical issues arising from the treatment.
The intervention being tested is QRX003, a 4% topical lotion applied twice daily. It is designed to alleviate symptoms of Netherton syndrome by acting as a serine protease inhibitor.
This open-label study follows a single-group intervention model without masking. Its primary purpose is treatment, focusing on the direct application of QRX003 to affected areas, excluding the scalp, over a 12-week period.
The study began on April 7, 2025, with the latest update submitted on July 16, 2025. These dates are crucial as they mark the study’s progress and ongoing recruitment status.
The study’s progress could influence Quoin Pharmaceuticals’ stock performance, as successful results might boost investor confidence. Given the niche market for Netherton syndrome treatments, positive outcomes could position Quoin as a leader in this area, potentially impacting competitors.
The study is currently recruiting, with further details available on the ClinicalTrials portal.